SOPHiA, Myriad Partner on Prostate Cancer Companion Diagnostic Development

SOPHiA GENETICS and Myriad Genetics collaborate to develop a prostate cancer companion diagnostic using PrGIS, a biomarker for homologous recombination deficiency. Myriad's MyChoice CDx test, currently used in ovarian cancer, will be expanded for prostate cancer. The partnership aims to evaluate PrGIS in clinical trials and enable global laboratory testing. Myriad will present research at the European Society for Medical Oncology Congress 2026.

Original reporting
Published Oct 16, 2026, 7:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 17, 2026, 5:15 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
SOPHiA, Myriad Partner on Prostate Cancer Companion Diagnostic Development — source image
Decision brief

The 30-second read

$MYGNNeutralLow
01

Why it matters

The deal expands both companies' precision oncology capabilities, potentially opening new revenue streams and enhancing market positioning in cancer diagnostics.

02

Market read

The collaboration could influence investor sentiment toward biotech diagnostic stocks and signal broader industry movement toward decentralized testing.

03

What to watch

Lack of disclosed funding amounts and timeline for clinical validation limits immediate impact.

Relevance 5/10Novelty 6/10Timing: today

Background

SOPHiA GENETICS and Myriad Genetics announced a collaboration to develop a prostate cancer-specific genomic instability score (PrGIS) as a companion diagnostic, with involvement from AstraZeneca and plans to present data at the ESMO Congress 2026.

Company-level read

Ticker impact

$MYGNNeutralMedium confidence
Context

Myriad Genetics announced a collaboration with SOPHiA GENETICS to develop a prostate cancer companion diagnostic.

Expected impact

potential modest upside as market prices in partnership

Evidence & confidence

No financial terms disclosed; impact depends on clinical validation progress.

$SOPHNeutralMedium confidence
Context

SOPHiA GENETICS entered a partnership with Myriad Genetics to integrate PrGIS technology into a decentralized companion diagnostic.

Expected impact

possible modest upside as investors value expanded market footprint

Evidence & confidence

Benefits hinge on successful clinical adoption; no monetary details provided.

Market effects

May boost the biotech diagnostic sector by highlighting precision oncology collaborations.

Both US and European markets could see slight interest in related stocks.

Reflects growing global focus on prostate cancer companion diagnostics.

Counterpoint

The partnership may not translate into near‑term revenue without disclosed financial terms.

Key entities

  • SOPHiA GENETICS

    Swiss biotech firm providing a cloud‑based platform for genomic testing.

  • Myriad Genetics

    US‑listed genetics company developing diagnostic tests, ticker MYGN.

  • AstraZeneca

    Pharma partner referenced in the collaboration.

Related articles

$MYGNHighAI 8/10

Myriad Genetics (MYGN) Q3 2026 Earnings Call Transcript

Myriad Genetics (MYGN) reported Q3 2026 revenue of $202.7M, with 4% volume growth in Cancer Care and 3% in Mental Health, offset by an 11% decline in Prenatal Health. The company announced the sale of its Prenatal Health business to Labcorp for $210M. Gross margin improved to 67.9%, and adjusted EBITDA and EPS showed sequential improvements. MYGN raised its 2026 revenue guidance to $780M-$790M, citing growth in Cancer Care and Mental Health tests.